BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Appelbaum FR, Anasetti C, Antin JH, Atkins H, Davies S, Devine S, Giralt S, Heslop H, Laport G, Lee SJ, Logan B, Pasquini M, Pulsipher M, Stadtmauer E, Wingard JR, Horowitz MM. Blood and marrow transplant clinical trials network state of the Science Symposium 2014. Biol Blood Marrow Transplant 2015;21:202-24. [PMID: 25445636 DOI: 10.1016/j.bbmt.2014.10.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Kaviany S, Kitko CL. The role of biomarkers in risk stratification, treatment and outcome in acute GVHD. Curr Opin Hematol 2021;28:401-7. [PMID: 34475350 DOI: 10.1097/MOH.0000000000000681] [Reference Citation Analysis]
2 Heslop HE, Stadtmauer EA, Levine JE, Ballen KK, Chen YB, DeZern AE, Eapen M, Hamadani M, Hamilton BK, Hari P, Jones RJ, Logan BR, Kean LS, Leifer ES, Locke FL, Maziarz RT, Nemecek ER, Pasquini M, Phelan R, Riches ML, Shaw BE, Walters MC, Foley A, Devine SM, Horowitz MM. Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year. Transplant Cell Ther 2021;27:885-907. [PMID: 34461278 DOI: 10.1016/j.jtct.2021.08.016] [Reference Citation Analysis]
3 Devine SM, Horowitz MM. Building a Fit for Purpose Clinical Trials Infrastructure to Accelerate the Assessment of Novel Hematopoietic Cell Transplantation Strategies and Cellular Immunotherapies. J Clin Oncol 2021;39:534-44. [PMID: 33434065 DOI: 10.1200/JCO.20.01623] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Farhadfar N, Burns LJ, Mupfudze T, Shaw BE, Bollard CM, Devine SM, Horowitz MM, Jones RJ, Murthy HS, Wingard JR, Lee SJ. Hematopoietic Cell Transplantation: Practice Predictions for the Year 2023. Transplant Cell Ther 2021;27:183.e1-7. [PMID: 33045387 DOI: 10.1016/j.bbmt.2020.10.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Pidala J, Hamadani M, Dawson P, Martens M, Alousi AM, Jagasia M, Efebera YA, Chhabra S, Pusic I, Holtan SG, Ferrara JLM, Levine JE, Mielcarek M, Anasetti C, Antin JH, Bolaños-Meade J, Howard A, Logan BR, Leifer ES, Pritchard TS, Horowitz MM, MacMillan ML. Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial. Blood 2020;135:97-107. [PMID: 31738834 DOI: 10.1182/blood.2019003125] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 11.0] [Reference Citation Analysis]
6 Shaw BE. Graft Versus Host Disease Clinical Trials: Is it Time for Patients Centered Outcomes to Be the Primary Objective? Curr Hematol Malig Rep 2019;14:22-30. [PMID: 30637541 DOI: 10.1007/s11899-019-0494-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Levine JE, Antin JH, Allen CE, Burroughs LM, Cooke KR, Devine S, Heslop H, Nakamura R, Talano JA, Yanik G, DiFronzo N. Priorities for Improving Outcomes for Nonmalignant Blood Diseases: A Report from the Blood and Marrow Transplant Clinical Trials Network. Biol Blood Marrow Transplant 2020;26:e94-e100. [PMID: 32035274 DOI: 10.1016/j.bbmt.2020.01.024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Petersdorf EW, Stevenson P, Malkki M, Strong RK, Spellman SR, Haagenson MD, Horowitz MM, Gooley T, Wang T. Patient HLA Germline Variation and Transplant Survivorship. J Clin Oncol 2018;36:2524-31. [PMID: 29902106 DOI: 10.1200/JCO.2017.77.6534] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Scordo M. An Old Friend Is Trouble for Double-Expressor and Double-Hit Lymphoma. Biol Blood Marrow Transplant 2018;24:421-2. [PMID: 29339272 DOI: 10.1016/j.bbmt.2018.01.012] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Wood WA, McGinn MK, Wilson D, Deal AM, Khera N, Shea TC, Devine SM, Appelbaum FR, Horowitz MM, Lee SJ. Practice Patterns and Preferences Among Hematopoietic Cell Transplantation Clinicians. Biol Blood Marrow Transplant 2016;22:2092-9. [PMID: 27481447 DOI: 10.1016/j.bbmt.2016.07.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
11 Steering Committee Of The Blood And Marrow Transplant Clinical Trials Network. The Blood and Marrow Transplant Clinical Trials Network: An Effective Infrastructure for Addressing Important Issues in Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 2016;22:1747-57. [PMID: 27418009 DOI: 10.1016/j.bbmt.2016.07.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
12 Elsawy M, Sorror ML. Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2016;51:1283-300. [PMID: 27272454 DOI: 10.1038/bmt.2016.141] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 7.7] [Reference Citation Analysis]
13 Satwani P, Kahn J, Jin Z. Making strides and meeting challenges in pediatric allogeneic hematopoietic cell transplantation clinical trials in the United States: Past, present and future. Contemporary Clinical Trials 2015;45:84-92. [DOI: 10.1016/j.cct.2015.06.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
14 Bejanyan N, Haddad H, Brunstein C. Alternative Donor Transplantation for Acute Myeloid Leukemia. J Clin Med 2015;4:1240-68. [PMID: 26239557 DOI: 10.3390/jcm4061240] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
15 Sorror ML, Logan BR, Zhu X, Rizzo JD, Cooke KR, McCarthy PL, Ho VT, Horowitz MM, Pasquini MC. Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study. Biol Blood Marrow Transplant 2015;21:1479-87. [PMID: 25862591 DOI: 10.1016/j.bbmt.2015.04.004] [Cited by in Crossref: 99] [Cited by in F6Publishing: 91] [Article Influence: 14.1] [Reference Citation Analysis]
16 Sorror ML. Defining vulnerability in allogeneic transplants is more complicated than the two numerical digits of age. Leuk Lymphoma 2015;56:2235-6. [PMID: 25832446 DOI: 10.3109/10428194.2015.1036260] [Reference Citation Analysis]